QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
QQQ   290.27 (-2.02%)
AAPL   143.00 (-2.01%)
MSFT   242.71 (-2.20%)
META   147.06 (-3.08%)
GOOGL   96.94 (-2.45%)
AMZN   100.55 (-1.65%)
TSLA   166.66 (-6.32%)
NVDA   191.62 (-5.91%)
NIO   12.02 (-5.43%)
BABA   111.20 (-6.07%)
AMD   72.45 (-3.91%)
T   20.16 (+1.05%)
MU   61.71 (-3.38%)
F   12.89 (-2.86%)
CGC   2.84 (-3.07%)
GE   80.83 (-2.88%)
DIS   107.59 (-1.78%)
AMC   5.01 (-9.07%)
PFE   43.55 (-0.55%)
PYPL   79.64 (-2.68%)
NFLX   353.11 (-2.12%)
NASDAQ:NTRA

Natera - NTRA Stock Forecast, Price & News

$41.98
-1.76 (-4.02%)
(As of 01/30/2023 12:00 AM ET)
Add
Compare
Today's Range
$41.32
$43.16
50-Day Range
$35.29
$43.74
52-Week Range
$26.10
$74.82
Volume
899,396 shs
Average Volume
1.42 million shs
Market Capitalization
$4.10 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$80.00

Natera MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
90.6% Upside
$80.00 Price Target
Short Interest
Bearish
6.48% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.03mentions of Natera in the last 14 days
Based on 10 Articles This Week
Insider Trading
Selling Shares
$1.91 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($5.64) to ($4.72) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

581st out of 1,049 stocks

Medical Laboratories Industry

17th out of 25 stocks


NTRA stock logo

About Natera (NASDAQ:NTRA) Stock

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. It offers Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother, as well as twin pregnancies for zygosity; Vistara, a single-gene mutations screening test to identify single-gene disorder; Horizon carrier screening to determine carrier status for various genetic diseases; and Spectrum to identify chromosomal anomalies or inherited genetic conditions during an in vitro fertilization cycle. The company also provides Anora miscarriage test products to analyze fetal chromosomes to understand the cause of miscarriage; and non-invasive paternity testing products to determine paternity by gestation using a blood draw from the pregnant mother and alleged father. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics in order to validate and launch tests; Signatera, a circulating tumor DNA technology that screen for a generic set of mutations independent of an individual's tumor; and Prospera used to assess organ transplant rejection. The company offers products through its direct sales force, as well as through a network of approximately 100 laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was formerly known as Gene Security Network, Inc. and changed its name to Natera, Inc. in 2012. Natera, Inc. was founded in 2003 and is based in Austin, Texas.

Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Stock News Headlines

Profit From the Commercial Solar Boom?
Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered.
Natera (NASDAQ:NTRA) Earns Overweight Rating from Piper Sandler
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Natera Third Quarter 2022 Earnings: Beats Expectations
Natera Reports Third Quarter 2022 Financial Results
Natera, Inc. (NTRA)
Natera: Cracks In The Bearish Trade
See More Headlines
Receive NTRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Natera and its competitors with MarketBeat's FREE daily newsletter.

NTRA Company Calendar

Last Earnings
11/08/2022
Today
1/30/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Medical laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NTRA
Fax
N/A
Employees
2,670
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$80.00
High Stock Price Forecast
$110.00
Low Stock Price Forecast
$55.00
Forecasted Upside/Downside
+90.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-471,720,000.00
Pretax Margin
-70.27%

Debt

Sales & Book Value

Annual Sales
$625.49 million
Book Value
$6.91 per share

Miscellaneous

Free Float
87,579,000
Market Cap
$4.10 billion
Optionable
Optionable
Beta
1.28

Key Executives

  • Dr. Matthew  Rabinowitz Ph.D.Dr. Matthew Rabinowitz Ph.D. (Age 50)
    Co-Founder & Exec. Chairman
    Comp: $502.21k
  • Mr. Steven Leonard ChapmanMr. Steven Leonard Chapman (Age 44)
    CEO, Pres & Director
    Comp: $925.59k
  • Mr. Michael B. Brophy M.B.A. (Age 43)
    Chief Financial Officer
    Comp: $661.5k
  • Mr. Robert A. SchuerenMr. Robert A. Schueren (Age 61)
    Chief Operating Officer
    Comp: $706.72k
  • Mr. Daniel  Rabinowitz L.L.M.Mr. Daniel Rabinowitz L.L.M. (Age 54)
    LL.M., Sec. & Chief Legal Officer
    Comp: $557.47k
  • Mr. Jonathan  Sheena M.Eng.Mr. Jonathan Sheena M.Eng. (Age 50)
    Co-Founder & Director
  • Ms. Olesya A. Anisimova CPA
    Chief Accounting Officer
  • Mr. Rishi Kacker
    Chief Technology Officer
  • Mr. Eric A. Evans
    Chief Scientific Officer
  • Mr. Phil Grinnell
    VP of Sales













NTRA Stock - Frequently Asked Questions

Should I buy or sell Natera stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Natera in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NTRA shares.
View NTRA analyst ratings
or view top-rated stocks.

What is Natera's stock price forecast for 2023?

7 Wall Street research analysts have issued 12 month target prices for Natera's shares. Their NTRA share price forecasts range from $55.00 to $110.00. On average, they expect the company's share price to reach $80.00 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for NTRA
or view top-rated stocks among Wall Street analysts.

How have NTRA shares performed in 2023?

Natera's stock was trading at $40.17 on January 1st, 2023. Since then, NTRA shares have increased by 8.9% and is now trading at $43.74.
View the best growth stocks for 2023 here
.

Are investors shorting Natera?

Natera saw a increase in short interest in January. As of January 15th, there was short interest totaling 6,320,000 shares, an increase of 17.7% from the December 31st total of 5,370,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is currently 3.9 days.
View Natera's Short Interest
.

When is Natera's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our NTRA earnings forecast
.

How were Natera's earnings last quarter?

Natera, Inc. (NASDAQ:NTRA) released its earnings results on Tuesday, November, 8th. The medical research company reported ($1.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.42) by $0.17. The medical research company had revenue of $210.64 million for the quarter, compared to analysts' expectations of $208.31 million. Natera had a negative net margin of 70.34% and a negative trailing twelve-month return on equity of 109.07%.

What guidance has Natera issued on next quarter's earnings?

Natera updated its FY 2022 earnings guidance on Thursday, December, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $810.00 million-$830.00 million, compared to the consensus revenue estimate of $819.07 million.

What is Steve Chapman's approval rating as Natera's CEO?

158 employees have rated Natera Chief Executive Officer Steve Chapman on Glassdoor.com. Steve Chapman has an approval rating of 91% among the company's employees. This puts Steve Chapman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Natera own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Natera investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), NIC (EGOV), Aegean Marine Petroleum Network (ANW), Micron Technology (MU), Transocean (RIG) and Allergan (AGN).

When did Natera IPO?

(NTRA) raised $101 million in an initial public offering (IPO) on Thursday, July 2nd 2015. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Morgan Stanle, Cowen and Company and Piper Jaffray acted as the underwriters for the IPO and Baird and Wedbush Pacgrow were co-managers.

What is Natera's stock symbol?

Natera trades on the NASDAQ under the ticker symbol "NTRA."

Who are Natera's major shareholders?

Natera's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.68%), Artemis Investment Management LLP (0.68%), Exchange Traded Concepts LLC (0.04%), Silvant Capital Management LLC (0.02%), Xponance Inc. (0.01%) and Maryland State Retirement & Pension System (0.01%). Insiders that own company stock include Daniel Rabinowitz, Gail Boxer Marcus, Herm Rosenman, James Healy, Jonathan Sheena, Matthew Rabinowitz, Michael Burkes Brophy, Patrick J Donovan, Robert Alan Schueren, Roelof Botha, Rowan E Chapman, Roy D Baynes, Steven Leonard Chapman, Todd C Cozzens and Todd C Cozzens.
View institutional ownership trends
.

How do I buy shares of Natera?

Shares of NTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Natera's stock price today?

One share of NTRA stock can currently be purchased for approximately $43.74.

How much money does Natera make?

Natera (NASDAQ:NTRA) has a market capitalization of $4.27 billion and generates $625.49 million in revenue each year. The medical research company earns $-471,720,000.00 in net income (profit) each year or ($5.68) on an earnings per share basis.

How many employees does Natera have?

The company employs 2,670 workers across the globe.

How can I contact Natera?

Natera's mailing address is 201 INDUSTRIAL ROAD SUITE 410, SAN CARLOS CA, 94070. The official website for the company is www.natera.com. The medical research company can be reached via phone at (650) 249-9090 or via email at mbrophy@natera.com.

This page (NASDAQ:NTRA) was last updated on 1/30/2023 by MarketBeat.com Staff